Now countries can try to counteract the influence of that kind of marketing, but if tobacco companies feel threatened, they’ll put them through legal hell. Let me take you on a world tour of how they attack laws intended to protect public health, because it’s kind of amazing.
Let’s start in Australia. In 2011, they passed a plain packaging law, and what that means is this. [Shows (fair use!) news clip describing required packaging of cigarettes with no branding, and scary health pictures]. Australia’s plain packaging law bans tobacco company branding from packaging and replaced it with upsetting photos, such as the toe tag on a corpse, the cancerous mouth, the nightmarish eyeball, or the diseased lung. Now, yes, I’m pretty sure I’d find a healthy lung disgusting, but, that thing does look like you’re trying to breathe through baked ziti, so [instructing staff] take it down! Just take it down!
Perhaps unsurprisingly, since this law was implemented, total consumption of tobacco cigarettes in Australia fell to record lows and… nightmares about eyeballs have risen to record highs. [Instructing staff] Take it down! Take down the demon eye!
To get these laws, though, Australia has had to run a gamut of lawsuits. First, two tobacco companies sued Australia in its highest court to stop them. The result, was a little surprising, as Australia’s attorney general let everyone know. [Shows clip of AG announcing not just the victory, but Big Tobacco having to pay the government’s legal fees.] Yes! Score one for the little guy! Even if that little guy is the sixth largest country in the world by landmass.
And the tobacco companies didn’t just lose. The judges called their case “delusive,” “unreal and synthetic” and said their case had “fatal defects.” ….
But Australia’s legal troubles were just beginning. Because then, Philip Morris Asia got involved. [Shows clips of a news report saying Philip Morris considering using ISDS provisions to take the Australian government to a tribunal claiming it lowered the value of the company’s trademarks].
That’s right. A company was able to sue a country over a public health measure, through an international court. How the fuck is that possible? Well, it’s really a simple explanation. They did it by digging up a 1993 trade agreement between Australia and Hong Kong which had a provision that said Australia couldn’t seize Hong Kong-based companies’ property. So, nine months before the lawsuits started, PMI put its Australian business in the hands of its Hong Kong-based Philip Morris Asia division, and then they sued, claiming that the “seized property” in question, were the trademarks on their cigarette packages.
And you’ve got to give it to them: that’s impressive. Someone should really give those lawyers a pat on the back… and a punch in the face. But, a pat on the back first. Pat, then punch. Pat, punch….
Category: Patents
EFF Responds to USTR Bullying the World to Repeat Our Copyright Mistakes
From the same agency that brought you the Trans-Pacific Partnership (TPP)—the United States Trade Representative (USTR)—comes a lesser-known, but also insidious global intellectual property gambit: the Special 301 Report. The Special 301 Report is a survey conducted under the auspices of the Trade Act and has been issued every year since 1989. The USTR, like a malevolent Santa Claus, assesses whether the other countries of the world have been naughty or nice in their treatment of U.S. intellectual property holders, and raps them over the knuckles if they don’t come up to scruff.
This would be absolutely fair enough, if the standards by which the other countries were assessed were globally-agreed standards, and if their adherence to those standards were assessed objectively, using a consistent and predictable methodology. But they’re not; rather, the USTR has free reign to castigate its trading partners for whatever reasons it can come up with. And it’s never short for ideas, because the International Intellectual Property Alliance (IIPA) and the Pharmaceutical Research and Manufacturers of America (PhRMA) supply complaints galore in the phonebook-length submissions that they file every year.
Once More With Feeling: Patent Reform Introduced, And This Time The Trial Lawyers May Not Be Able To Kill It
This was widely expected, but Rep. Goodlatte has now officially re-introduced his patent reform bill, which largely mirrors the one that sailed through the House with ease a little over a year ago (in part because they took out some of the key parts). The Senate bill was a bit stronger and was on the verge of passing until the trial lawyers called up Senator Harry Reid, and had him flat out kill the bill, despite widespread bipartisan support. As we noted at the time, it seemed like the trial lawyers may have miscalculated, because it was already clear that the Republicans were likely to gain control over the Senate in the 2014 elections (as they did), and they were not interested in bowing down to the trial lawyers.
Defining The Patent Troll
Recently, the IP Troll Tracker blog decided to try to officially define “patent troll” to a level that might satisfy a patent holder who insists that there is no such thing as a patent troll. For many years, we here at Techdirt avoided using the phrase “patent troll” because it did seem rather undefined, but it became so commonplace that we eventually gave in and used the phrase regularly. The term has showed up in all sorts of places, including courtrooms and discussions on legislation. In some circles, policy makers often use the term “non-practicing entities” (or NPEs) instead of “patent trolls” but that upsets some who feel that there are “NPEs” (like universities) that do research that they wish to license off, but which will never be “practicing entities.” Some have also called them “Patent Assertion Entities” (PAEs) to describe companies who do nothing more than assert patents. At least that leaves out universities — but then that also leaves out companies who do other things but who also, do some patent trolling (including, frankly, some universities, since we’re discussing them).
Stephanie Kennedy, who runs the IP Troll Tracker blog, came up with the following definition:
Patent Troll, n –
1/ A company or individual who, using patents that either never should have been issued or are broadly constructed (intentionally for the purpose of misuse, or as a result of poor USPTO patent examination practices), sends letters to various and sundry companies and/or individuals that simultaneously request license fees and threaten legal action if the recipient fails to respond correctly by paying up and who will, in the face of inaction by a demand letter recipient, actually file suit in Federal District Court, the District of East Texas being the most popular venue.2/ A company set up to act as a cover for large corporations who try to breathe new life into older patents which they would ordinarily let expire but, as a result of greed and/or pressure from Wall Street, have decided are ripe for assertion or litigation.
3/ Intellectual Ventures
Stupid Patent of the Month: Who Wants to Buy Teamwork From Penn State?
Ever wanted to own the latest in “teamwork” technology? Well, you’re in luck. On December 8, Penn State is holding a large patent auction, and one of the items is U.S. Patent 8,442,839. This patent purports to describe an improved collaborative “decision-making process.” As well as being a good example of a silly patent, this month’s winner highlights concerns with universities trying to monetize their patent portfolio. Why would a university, which presumably has a mission of promoting knowledge and innovation, sell an unsuccessful patent that has no value except to a troll?
Pharma Officials Insist That There Is ‘Zero Evidence’ That Patents Harm Access To Medicine
Eli Lilly has claimed on Twitter that there is no evidence drug patents harm access to medicine.
More Abuse Of The Orphan Drug System: Taking Treatment From Free To $80,000 A Year
Catalyst Pharmaceutical Partners, which has just reported what seems like good news for those suffering from Lambert-Eaton Myasthenic Syndrome (LEMS), a progressive, muscle-weakening disease. Catalyst has announced positive results from a final phase trial of a drug called “Firdapse.” As The Street article reports, analysts believe that once approved by the US Food and Drug Administration, Firdapse could cost between $60,000 and $80,000 per year if it is designated an orphan drug, which brings with it seven years of marketing exclusivity. That might seem the going rate for new drugs, but there’s a nasty twist in this tale, as Feuerstein notes:
Firdapse is not a new treatment for LEMS. The active ingredient in Firdapse is a compound known as 3,4-Dap, which has been available in the U.S. for more than 20 years. Doctors treating the small numbers of LEMS patients in the U.S. can obtain inexpensive 3,4-Dap from compounding pharmacies. It’s even given away for free to doctors and patients by a tiny New Jersey drug maker, Jacobus Pharmaceuticals.
That means that Catalyst took no risks with Firdapse. Indeed, it didn’t really do anything at all
Serial Litigant Blue Spike Wins September’s Stupid Patent of the Month
Blue Spike LLC is a patent litigation factory. At one point, it filed over 45 cases in two weeks. It has sued a who’s who of technology companies, ranging from giants to startups, Adobe to Zeitera. Blue Spike claims not to be a troll, but any legitimate business it has pales in comparison to its patent litigation. It says it owns a “revolutionary technology” it refers to as “signal abstracting.” On close inspection, however, its patents1 turn out to be nothing more than a nebulous wish list. Blue Spike’s massive litigation campaign is a perfect example of how vague and abstract software patents tax innovation.
Keith Alexander Defends Patenting His Totally Brand New, Not Developed On Gov’t Time, Patent-Pending Cybersecurity Brilliance
“If I retired from the Army as a brain surgeon, wouldn’t it be OK for me to go into private practice and make money doing brain surgery?” he asked. “I’m a cyber guy. Can’t I go to work and do cyber stuff?”
The “brain surgery” analogy is not even close to be analogous. This is more like he was the administrator of an army hospital who has now retired and says, despite never having personally done a brain surgery, he’s now invented a miraculous new way to do brain surgeries so powerful people have only dreamed of them before. Naturally, most people should be skeptical of such claims.
Is the European Patent Office a rogue state?
It would be easy to assume that the European Patent Office (EPO) stands in the same relationship to the European Union as the USPTO does to the United States, but that’s actually wide of the mark. The EPO is a very strange beast indeed, as its Wikipedia entry makes clear:
The premises of the European Patent Office enjoy a form of extraterritoriality. In accordance with the Protocol on Privileges and Immunities, which forms an integral part of the European Patent Convention under Article 164(1) EPC, the premises of the European Patent Organisation, and therefore those of the European Patent Office, are inviolable. The authorities of the States in which the Organisation has its premises are not authorized to enter those premises, except with the consent of the President of the European Patent Office.